0001757073FALSE00017570732024-07-152024-07-15

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________________
FORM 8-K
_____________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): July 15, 2024
_____________________________________________
envistalogoa26.jpg
ENVISTA HOLDINGS CORPORATION
(Exact Name of Registrant as Specified in Its Charter)
_____________________________________________
Delaware
(State or Other Jurisdiction of Incorporation)
001-3905483-2206728
(Commission File Number)(IRS Employer Identification No.)
200 S. Kraemer Blvd., Building E92821
Brea,California
(Address of Principal Executive Offices)(Zip Code)
(714) 817-7000
(Registrant’s Telephone Number, Including Area Code)
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
_____________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock, $0.01 par value NVST New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company      ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐





ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS

On July 15, 2024, Envista Holdings Corporation (the “Company”) announced that it has appointed Eric Hammes as the Senior Vice President and Chief Financial Officer of the Company, with such appointment to be effective as of August 8, 2024.

Mr. Hammes, age 49, served as Vice President, Corporate Financial Planning & Analysis of Rockwell Automation, a global industrial automation company from August 2023 to July 2024. Prior to that, Mr. Hammes served at 3M Company as Executive Vice President, Chief Country Governance and Services Officer from January 2022 to May 2023, Executive Vice President, Enterprise Operations from April 2019 to December 2021, Executive Vice President, Business Transformation & IT from June 2017 to April 2019, and Senior Vice President, Controller and Chief Accounting Officer from April 2014 to April 2017. Mr. Hammes joined 3M in 1997 and held various financial and leadership roles including CFO of 3M Health Care Business Group, Director Finance of 3M Orthodontic Products Division, and Senior Vice President, International Finance.

Mr. Hammes' compensation in summary will consist of: a base annual salary of $575,000, target annual incentive compensation equal to 75% of base salary, target value of annual long-term incentive award of $1,200,000, a one-time lump sum bonus of $1,020,000 (subject to a 12-month clawback period), a one-time award of restricted stock units valued at $1,200,000 vesting ratably on each anniversary of the date of grant over three years, and customary relocation allowances and company benefits.

Mr. Hammes does not have any family relationships with any director, executive officer or person nominated or chosen by the Company to become a director or executive officer of the Company. The Company is not aware of any related transactions or relationships between Mr. Hammes and the Company that would require disclosure under Item 404(a) of Regulation S-K. There are no arrangements or understandings between Mr. Hammes and any other person pursuant to which Mr. Hammes was selected as an officer of the Company.

ITEM 7.01 REGULATION FD DISCLOSURE

On July 15, 2024, the Company issued a press release announcing recent appointments to the Company’s leadership team, including Mr. Hammes' appointment as Chief Financial Officer. A copy of the release is furnished herewith as Exhibit 99.1 and incorporated by reference herein.

The information included or incorporated by reference in this Item 7.01 is being furnished to the SEC and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits.
Exhibit No. Description
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 ENVISTA HOLDINGS CORPORATION
   
   
Date: July 15, 2024By:/s/ Mark Nance
  Mark Nance
  Senior Vice President, General Counsel and Secretary



Exhibit 99.1
Envista Holdings Corporation Announces Key Leadership Appointments

BREA, Calif., July 15, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced the following key leadership appointments:

•Eric Hammes joins Envista as Chief Financial Officer
•Stefan Nilsson joins Envista as President, Nobel Biocare
•Veronica Acurio joins Envista as President, Ormco

“It is a pleasure to welcome this trio of successful leaders to Envista,” said Paul Keel, Chief Executive Officer. “Each brings experience in dental along with a proven track record of continuous improvement, leading with purpose, and creating value for all stakeholders. Today’s announcement positions Envista even more strongly to advance our mission of partnering with dental professionals to improve patient lives.”

Eric Hammes – Chief Financial Officer

Eric Hammes is appointed Chief Financial Officer effective August 8, 2024. He succeeds Stephen Keller who has served as Interim Principal Financial Officer since September 2023. Mr. Keller will return to his previous role leading investor relations.

Mr. Hammes brings more than 25 years of operational and financial leadership to Envista. He joins the company from Rockwell Automation, where he served has Vice President, Corporate Financial Planning and Analysis. Prior to Rockwell, Eric had an extensive career at 3M where he held numerous financial and operational leadership positions including Senior Vice President Controller and Chief Accounting Officer, CFO of 3M Health Care Business Group, and Director Finance for the Orthodontic Products Division.
Mr. Keel said, “We are proud to have Eric join us as CFO. He is a transformational leader with a strong track record of delivering continuous improvement and increasing shareholder value. He has directly relevant experience in both dental and health care as well as multi-segment global businesses. Eric is well positioned to help our leadership team accelerate Envista’s growth, expand our margins, and further advance our portfolio.”
Mr. Hammes said, “I am thrilled to join Envista at this exciting time in the company’s history. Envista’s leading brands in the most attractive dental segments, and its commitment to continuous improvement, positions Envista well for long-term value creation for all stakeholders.”
Stefan Nilsson – President, Nobel Biocare
Stefan Nilsson is appointed President of Nobel Biocare, effective July 15, 2024.

Most recently, Mr. Nilsson served as CEO of Colosseum Dental Group, which grew to be one of Europe’s largest Dental Service Organizations under his leadership. Prior to Colosseum, Mr. Nilsson was CEO of GrandVision Brazil, a leading eyecare service provider. Further, he had a distinguished career at Nestle in a variety of operations, marketing, and general management roles around the world.


Mr. Keel said, “It is my pleasure to welcome Stefan to Envista. As CEO of Colosseum Dental Group, Stefan led the company through a period of rapid growth and value creation. He has deep insights into the ever-evolving needs of our customers, and he is a passionate advocate for the digitization of dental workflows. I look forward to working with Stefan to accelerate growth at Nobel Biocare and further position us as a global leader in implant dentistry.”
Mr. Nilsson said, “It is an honor to join Envista as President of Nobel Biocare, the premier brand in implants. Nobel is the pioneer of implant innovation and well positioned to lead the future of this specialty. As a customer, I saw firsthand the strength of Nobel Biocare’s innovation, their best-in-class clinical solutions, and the vibrant community of clinicians around the brand. I am delighted to be working with the Nobel team and our clinical partners to further advance our business and the future of implant dentistry.”
Veronica Acurio – President, Orthodontics
Veronica Acurio is appointed President, Orthodontics effective August 2, 2024.
Ms. Acurio joins Envista from Solventum, a global medical device business recently spun off from 3M Company. Veronica has extensive experience in profitably growing global health care businesses. Most recently, she served as President of 3M’s $5 billion Medical Solutions Division. Prior to that, she held various commercial, operational, and business leadership roles around the world including SVP of 3M Health Care in the Greater China region, Managing Director of 3M Taiwan, VP Business Development of 3M Health Care for Latin America, and Global Business Director of 3M Oral Care Division’s Restorative business.

Mr. Keel said, “We are delighted to welcome Veronica to Envista. She is an accomplished leader with a proven track record of leading dental and medical businesses all around the world. Her passionate focus on customers and innovation ideally positions Veronica to further advance Ormco as the partner of choice for orthodontic specialists.”

Ms. Acurio said, “I am humbled to join Envista as President of Orthodontics. Envista has long been a leader in orthodontics. The Ormco business has partnered with the orthodontic community for over 60 years bringing innovation in both bracket and wires and clear aligners. SparkTM aligners is one of the fastest growing brands in dental. It is a privilege to lead this business in helping orthodontists improve the smiles of millions of patients globally.”

ABOUT ENVISTA HOLDINGS CORPORATION
Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr united by a shared purpose: to partner with professionals to improve lives. Envista helps its customers deliver the best possible patient care through industry-leading dental consumables, solutions, technology, and services. Its comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers a wide range of dentists' clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the aesthetics of the human smile. With a foundation comprised of the proven Envista Business System (EBS) methodology, an experienced leadership team, and a strong culture grounded in continuous improvement, commitment to innovation, and deep customer focus, Envista is well equipped to meet the end-to-end needs of dental professionals worldwide. Envista is one of the largest global dental products companies, with significant


market positions in some of the most attractive segments of the dental products industry. For more information, please visit www.envistaco.com. 
FOR FURTHER INFORMATION 
Melissa Morrison 
Vice President, Communication
Envista Holdings Corporation 
200 S. Kraemer Blvd., Building E 
Brea, CA 92821 
Telephone: (714) 817-7000 
SOURCE Envista Holdings Corporation 

v3.24.2
Cover
Jul. 15, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jul. 15, 2024
Entity Registrant Name ENVISTA HOLDINGS CORPORATION
Entity Incorporation, State or Country Code DE
Entity File Number 001-39054
Entity Tax Identification Number 83-2206728
Entity Address, Address Line One 200 S. Kraemer Blvd., Building E
Entity Address, City or Town Brea,
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92821
City Area Code 714
Local Phone Number 817-7000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $0.01 par value
Trading Symbol NVST
Security Exchange Name NYSE
Entity Emerging Growth Company false
Entity Central Index Key 0001757073
Amendment Flag false
Envista (NYSE:NVST)
Historical Stock Chart
Von Dez 2024 bis Jan 2025 Click Here for more Envista Charts.
Envista (NYSE:NVST)
Historical Stock Chart
Von Jan 2024 bis Jan 2025 Click Here for more Envista Charts.